David H. Kirn, MD, Founder, President and Chief Executive Officer, is a medical oncologist and a leader in cancer product research and commercial development. He held academic positions at Harvard Medical School; the University of California, San Francisco; and the University of Oxford where he is currently an adjunct Professor. Dr. Kirn was Vice President of Clinical Research at Onyx Pharmaceuticals. After joining as the first oncology development employee, he created and initiated clinical development plans in partnership with Bayer for Nexavar, now a marketed product for kidney cancer. He also led the development of a first-in-class oncolytic virus therapeutic through to Phase III and a corporate partnership with Warner-Lambert. Onyx completed an Initial Public Offering during his tenure. Dr. Kirn subsequently consulted for Pfizer, Novartis, BiogenIdec, Schering AG and other leading oncology companies. He was an invited advisor on cancer therapy to the National Institutes of Health (U.S.), the Gene Therapy Advisory Committee (U.K.) and the European Agency for the Evaluation of Medicinal Products (E.U.). He is author of over 70 publications in peer-reviewed journals and textbooks.  He founded the International Society of Oncolytic Virotherapy with Dr. Bell in 2007.

John Bell, PhD, Chief Scientific Officer. Dr. Bell completed his PhD in Virology and Immunology at McMaster University and then carried out post-doctoral studies at the Medical Research Council in London England. In 1986, he began his independent research career at McGill University in the Department of Biochemistry supported by a Medical Research Council Scholarship and subsequently as a Senior Scientist of the National Cancer Institute of Canada. Dr. Bell moved to the Department of Medicine at the University of Ottawa in 1989 and is currently a Senior Scientist at the Ottawa Health Research Institute. In 2004 Dr. Bell formed and continues to head the Canadian Oncolytic Virus Consortium, a peer reviewed and funded multi-disciplinary group from across Canada that is developing virus based cancer therapeutics. In 2007, Dr. Bell was named the Director of the Ontario Institute for Cancer Research program in Biotherapeutics, a program comprised of scientists and clinicians from across Ontario whose aim is to exploit viral and immuno-therapeutics to improve outcomes for cancer patients. Dr. Bell currently sits on the Board of Directors for the Canadian Cancer Society and is an Executive Member of the National Cancer Institute of Canada Clinical Trials Group. His research program has been continuously funded by peer reviewed grants for twenty three years and he is an author on over 90 publications.

Gregory W. Schafer, Senior Vice President and Chief Financial Officer. Mr. Schafer joined Jennerex as senior vice president and chief financial officer in June 2010 and has more than 20 years of broad functional and strategic leadership expertise. He has raised over $600 million in public and private transactions to fund biotechnology product development and commercialization activities. Most recently, he served as chief financial officer of Onyx Pharmaceuticals, Inc., where he was responsible for finance, accounting, risk management, and strategic and operational planning. Prior to Onyx, he served as chief financial officer and vice president of finance for Cerus Corporation, where he played a key role in transitioning the company from early-stage development to a commercial enterprise with an approved product. Prior to Cerus, Mr. Schafer worked as a management consultant for Deloitte and Touche, LLP and as an engineer specializing in biologics manufacturing. Mr. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company. He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.

Helena Chaye, PhD, LL.B., Vice President, Legal Affairs. Dr. Chaye has over 10 years of experience in business development, law, intellectual property management, technology transfer and licensing, and legal affairs. Her legal practice included providing advice on general corporate commercial matters, mergers acquisitions, and corporate finance. She represented venture capital funds in hi-tech and biotech financings. She was Business Development Manager for the Canadian Genetic Diseases Network where she directed the commercialization strategy of early stage technologies from member institutes by either forming partnerships with industry or by spinning-out new corporate entities. At MediGene, Inc. she was Director of Business Development. She led in-licensing and out-licensing of technologies for the oncolytic virus product programs, as well as the intellectual property strategies. She received her PhD in Genetics from the University of British Columbia and her Law degree from Dalhousie University.